Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Water pill could boost kidney Drug's power and cut side effects

NCT ID NCT05373264

Disease control Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 3 times

Summary

This study tests whether adding a common water pill (hydrochlorothiazide) to the standard drug tolvaptan can slow kidney function decline and reduce side effects like frequent urination in people with autosomal dominant polycystic kidney disease (ADPKD). About 300 adults on a stable dose of tolvaptan will receive either hydrochlorothiazide or a placebo. The goal is to improve both treatment effectiveness and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Jul 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ADPKD diagnosis (modified Ravine criteria) * ≥18 years old * eGFR \> 25 mL/min/1.73m2 * On stable treatment with the highest tolerated dose of V2RA for a minimum of 3 months Exclusion Criteria: * Known intolerance to hydrochlorothiazide * Use of any diuretic * Orthostatic hypotension complaints or blood pressure \<105/65mmHg during screening visit * Uncontrolled hypertension (blood pressure \>160/100mmHg) * Hypokalemia (\<3.5 mmol/L) * History of active gout on maintenance preventive treatment for gout (allopurinol, desuric and/or colchicine), defined as ≥2 episodes during the last year * History of skin cancer (basal cell, squamous cell and melanoma)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADPKD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant polycystic kidney disease Polyuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADPKD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    25 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam University Medical Center

    RECRUITING

    Amsterdam, Netherlands

  • Centre Hôpital Universitaire de Lyon

    RECRUITING

    Lyon, France

  • Charité University Hospital

    RECRUITING

    Berlin, Germany

  • Cliniques Universitaires Saint-Luc

    RECRUITING

    Brussels, Belgium

  • Erasmus University Medical Center

    RECRUITING

    Rotterdam, Netherlands

  • Fundación Puigvert

    RECRUITING

    Barcelona, Spain

  • Hospital La Cavale Blanche

    RECRUITING

    Brest, France

  • Hospital Universitario Mancha Centro

    RECRUITING

    Alcázar de San Juan, Spain

  • Hospital Universitario Vall D'Hebron

    RECRUITING

    Barcelona, Spain

  • Hôpital Fribourgeois (HFR)

    RECRUITING

    Fribourg, Switzerland

  • Hôpital Pellegrin (CHU Bordeaux)

    RECRUITING

    Bordeaux, France

  • Hôpitaux Universitaires de Genève (HUG)

    RECRUITING

    Geneva, Switzerland

  • Hôpitaux de Brabois (CHRU)

    RECRUITING

    Nancy, France

  • La Fundación Jiménez Díaz

    RECRUITING

    Madrid, Spain

  • Med. Klinik und Poliklinik III, Universitätsklinikum Dresden.

    RECRUITING

    Dresden, Germany

  • Medizinische Universität Innsbruck

    RECRUITING

    Innsbruck, Austria

  • Necker-Enfants Malades Hospital

    RECRUITING

    Paris, France

  • Uniklinikum Graz

    RECRUITING

    Graz, Austria

  • Universitair Ziekenhuis Antwerpen (UZA)

    RECRUITING

    Antwerp, Belgium

  • University Hospital Cologne

    RECRUITING

    Cologne, Germany

  • University Hospital Leuven

    RECRUITING

    Leuven, Belgium

  • University Medical Center Groningen

    RECRUITING

    Groningen, Netherlands

  • Universitätsklinikum Leipzig

    RECRUITING

    Leipzig, Germany

  • Universitätsspital Bern (Inselsspital)

    RECRUITING

    Bern, Switzerland

  • Universitätsspital Zürich (USZ)

    RECRUITING

    Zurich, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.